ILLUMIVIZ
Samsung Bioepis Co., Ltd.
Trademark Registered: 2022-10-04
Trademark Application Details
NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79324287 |
| Registration Number | 6861685 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
Timeline
| 2021-09-06 | Application Filed |
| 2021-10-28 | Location: INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM) |
| 2021-10-28 | Status: Live/Pending |
| 2021-11-08 | Transaction Date |
| 2022-10-04 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  SAMSUNG BIOEPIS CO., LTD. |
| Address | 76, Songdogyoyuk-ro, Yeonsu-gu Incheon KR |
| Legal Entity Type | Corporation |
| Legal Entity State | KR |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations for treating neovascular age-related macular degeneration; pharmaceutical preparations for treating diabetic macular edema; pharmaceutical preparations for the treatment of angiogenesis diseases and disorders; eye drops; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for ocular or intraocular surgery; ocular pharmaceuticals; ophthalmic preparations; pharmaceutical preparations for treating diabetes; human vaccine preparations; preparations for medical use, namely, preparations, biological formulations, biological preparations, antibody formulations and protein formulations for immunoregulation and for the treatment of immunologic disorders, autoimmune diseases, inflammatory diseases, arthritis, cancer, tumor, central nervous system disorders and metabolic diseases; pharmaceutical preparations for the treatment of inflammatory diseases; antidiabetic preparations; pharmaceutical preparations for the treatment of metabolic diseases and disorders; pharmaceutical preparations for the prevention of ocular disorders or diseases; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; dietary supplements |
| GS0051 | Pharmaceutical preparations for treating neovascular age-related macular degeneration; pharmaceutical preparations for treating diabetic macular edema; pharmaceutical preparations for the treatment of angiogenesis diseases and disorders; eye drops; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for ocular or intraocular surgery; ocular pharmaceuticals; ophthalmic preparations; pharmaceutical preparations for treating diabetes; human vaccine preparations; preparations for medical use, namely, preparations, biological formulations, biological preparations, antibody formulations and protein formulations for immunoregulation and for the treatment of immunologic disorders, autoimmune diseases, inflammatory diseases, arthritis, cancer, tumor, central nervous system disorders and metabolic diseases; pharmaceutical preparations for the treatment of inflammatory diseases; antidiabetic preparations; pharmaceutical preparations for the treatment of metabolic diseases and disorders; pharmaceutical preparations for the prevention of ocular disorders or diseases; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; dietary supplements |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2021-10-28 | 1 REPR M: |
| LIMITATION FROM ORIGINAL APPLICATION ENTERED | 2021-11-04 | 2 LIMI I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2021-11-08 | 3 NWOS I:Incoming Correspondence |
| APPLICATION FILING RECEIPT MAILED | 2021-11-12 | 4 MAFR O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2022-06-09 | 5 DOCK D:Assigned to Examiner |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2022-06-14 | 6 CNSA O:Outgoing Correspondence |
| NOTICE OF PUBLICATION | 2022-06-29 | 7 NPUB O:Outgoing Correspondence |
| NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | 2022-06-29 | 8 OP2R P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2022-06-29 | 9 OPNS P: |
| PUBLISHED FOR OPPOSITION | 2022-07-19 | 10 PUBO A:Allowance for Publication |
| NOTIFICATION PROCESSED BY IB | 2022-07-19 | 11 GPNX P: |
| REGISTERED-PRINCIPAL REGISTER | 2022-10-04 | 12 R.PR A:Allowance for Publication |
| GRANT OF PROTECTION CREATED, TO BE SENT TO IB | 2022-11-03 | 13 GPAR P: |
| FINAL DISPOSITION PROCESSED | 2022-11-14 | 14 FIMP P: |
| FINAL DISPOSITION NOTICE SENT TO IB | 2022-11-14 | 15 FICS P: |
| NOTIFICATION PROCESSED BY IB | 2022-12-04 | 16 GPNX P: |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 